Urba WJ - Search Results

1

An NMR blood test for cancer: a critical assessment.

Chmurny GN, Hilton BD, Halverson D, McGregor GN, Klose J, Issaq HJ, Muschik GM, Urba WJ, Mellini ML, Costello R, et al. Chmurny GN, et al. Among authors: urba wj. NMR Biomed. 1988 Jun;1(3):136-50. doi: 10.1002/nbm.1940010307. NMR Biomed. 1988. PMID: 3079310 Review.

2

Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects.

Ewel CH, Urba WJ, Kopp WC, Smith JW 2nd, Steis RG, Rossio JL, Longo DL, Jones MJ, Alvord WG, Pinsky CM, et al. Ewel CH, et al. Among authors: urba wj. Cancer Res. 1992 Jun 1;52(11):3005-10. Cancer Res. 1992. PMID: 1591717 Clinical Trial.

3

Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer.

Urba WJ, Steis RG, Longo DL, Kopp WC, Maluish AE, Marcon L, Nelson DL, Stevenson HC, Clark JW. Urba WJ, et al. Cancer Res. 1990 Jan 1;50(1):185-92. Cancer Res. 1990. PMID: 2293554

4

The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies.

Smith JW 2nd, Urba WJ, Curti BD, Elwood LJ, Steis RG, Janik JE, Sharfman WH, Miller LL, Fenton RG, Conlon KC, et al. Smith JW 2nd, et al. Among authors: urba wj. J Clin Oncol. 1992 Jul;10(7):1141-52. doi: 10.1200/JCO.1992.10.7.1141. J Clin Oncol. 1992. PMID: 1607919 Clinical Trial.

5

Enhancement of natural killer activity in human peripheral blood by flavone acetic acid.

Urba WJ, Longo DL, Lombardo FA, Weiss RB. Urba WJ, et al. J Natl Cancer Inst. 1988 Jun 1;80(7):521-5. doi: 10.1093/jnci/80.7.521. J Natl Cancer Inst. 1988. PMID: 2452890

6

Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine.

Urba WJ, Hartmann LC, Longo DL, Steis RG, Smith JW 2nd, Kedar I, Creekmore S, Sznol M, Conlon K, Kopp WC, et al. Urba WJ, et al. Cancer Res. 1990 May 15;50(10):2979-86. Cancer Res. 1990. PMID: 1692252

7

Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: a phase IA/B study.

Urba WJ, Ewel C, Kopp W, Smith JW 2nd, Steis RG, Ashwell JD, Creekmore SP, Rossio J, Sznol M, Sharfman W, et al. Urba WJ, et al. Cancer Res. 1992 May 1;52(9):2394-401. Cancer Res. 1992. PMID: 1533172 Clinical Trial.

8

Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia.

Steis RG, Marcon L, Clark J, Urba W, Longo DL, Nelson DL, Maluish AE. Steis RG, et al. Blood. 1988 May;71(5):1304-9. Blood. 1988. PMID: 3129046 Free article.

9

Recent National Cancer Institute lymphoma trials of etoposide-containing combination chemotherapy.

Urba WJ, Wilson WH, Duffey PL, Wittes R, Chabner BA, Longo DL. Urba WJ, et al. Semin Oncol. 1992 Dec;19(6 Suppl 13):26-32. Semin Oncol. 1992. PMID: 1283467 Review.

10

Immunoregulation in cancer-bearing hosts. Down-regulation of gene expression and cytotoxic function in CD8+ T cells.

Loeffler CM, Smyth MJ, Longo DL, Kopp WC, Harvey LK, Tribble HR, Tase JE, Urba WJ, Leonard AS, Young HA, et al. Loeffler CM, et al. Among authors: urba wj. J Immunol. 1992 Aug 1;149(3):949-56. J Immunol. 1992. PMID: 1353099

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

215 results

Search Page

Filters